Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walid Fakhouri

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
International Journal of Environmental Research and Public Health|June 2, 2021
Treatment Patterns and Pharmacoutilization in Patients Affected by Rheumatoid Arthritis in Italian SettingsValentina Perrone, Serena Losi, Veronica Rogai, et al.
Open Access Rheumatology : Research and Reviews|August 22, 2018
Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysisWalid Fakhouri, Pedro Lopez-Romero, Silvia Antonelli, et al.
Rheumatology and Therapy|December 17, 2024
Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational StudyPeter C Taylor, Walid Fakhouri, Samuel Ogwu, et al.
Rheumatology International|March 23, 2018
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritisBruno Fautrel, Rieke Alten, Bruce Kirkham, et al.
Rheumatology and Therapy|July 7, 2025
Patient Profile and Outcomes Among Patients with Rheumatoid Arthritis Treated with Baricitinib Versus Other Therapies in Spain: The RA-BE-REAL StudyMª Luz García-Vivar, Águeda Prior-Español, Walid Fakhouri, et al.
Clinical Rheumatology|June 5, 2019
Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategyPeter M Ten Klooster, Martijn A H Oude Voshaar, Walid Fakhouri, et al.
Cancer Treatment and Research Communications|February 12, 2026
Treatment and outcomes of patients with HR+/HER2- early breast cancer in a real-world setting in GermanyKlaus-Ulrich Däßler, Volker Petersen, Mark-Oliver Zahn, et al.
Rheumatology and Therapy|October 13, 2022
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim AnalysisRieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Arthritis Research & Therapy|November 14, 2019
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registryPeter M Ten Klooster, Letty G A Versteeg, Martijn A H Oude Voshaar, et al.
Future Oncology (London, England)|August 8, 2024
Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and SpainIsabel Blancas, Jessica Grosjean, Rebecca Pedersini, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
International Journal of Environmental Research and Public Health|June 2, 2021
Treatment Patterns and Pharmacoutilization in Patients Affected by Rheumatoid Arthritis in Italian SettingsValentina Perrone, Serena Losi, Veronica Rogai, et al.
Open Access Rheumatology : Research and Reviews|August 22, 2018
Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysisWalid Fakhouri, Pedro Lopez-Romero, Silvia Antonelli, et al.
Rheumatology and Therapy|December 17, 2024
Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational StudyPeter C Taylor, Walid Fakhouri, Samuel Ogwu, et al.
Rheumatology International|March 23, 2018
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritisBruno Fautrel, Rieke Alten, Bruce Kirkham, et al.
Rheumatology and Therapy|July 7, 2025
Patient Profile and Outcomes Among Patients with Rheumatoid Arthritis Treated with Baricitinib Versus Other Therapies in Spain: The RA-BE-REAL StudyMª Luz García-Vivar, Águeda Prior-Español, Walid Fakhouri, et al.
Clinical Rheumatology|June 5, 2019
Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategyPeter M Ten Klooster, Martijn A H Oude Voshaar, Walid Fakhouri, et al.
Cancer Treatment and Research Communications|February 12, 2026
Treatment and outcomes of patients with HR+/HER2- early breast cancer in a real-world setting in GermanyKlaus-Ulrich Däßler, Volker Petersen, Mark-Oliver Zahn, et al.
Rheumatology and Therapy|October 13, 2022
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim AnalysisRieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, et al.
Arthritis Research & Therapy|November 14, 2019
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registryPeter M Ten Klooster, Letty G A Versteeg, Martijn A H Oude Voshaar, et al.
Future Oncology (London, England)|August 8, 2024
Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and SpainIsabel Blancas, Jessica Grosjean, Rebecca Pedersini, et al.
Pageof 3